Comparison of antibody-based immunotherapeutics for malignant hematological disease in an experimental murine model.

Antibody-based immunotherapies have revolutionized leukemia and lymphoma treatment, with animal studies being crucial in evaluating effectiveness and side effects. By targeting the evolutionary conserved Slamf7 immune receptor, which is naturally expressed by the murine multiple myeloma cell line MPC-11, we have developed a syngeneic mouse model for direct comparison of 3 immunotherapies: monoclonal antibodies (mAb), bispecific T-cell engagers (BiTE), and chimeric antigen receptor (CAR) T cells (CART), all targeting Slamf7. Slamf7-BiTE is a bispecific single-chain antibody consisting of α-Slamf7 and α-CD3 Fv fragments joined through a Gly-Ser linker, and Slamf7-CART comprises the α-Slamf7 Fv fragment fused to the msCD8α transmembrane and msCD28, 4-1BB, and CD3ζ intracellular signaling domains.

Drug-Related Problems Increase Healthcare Costs for People Living with Dementia.

Background: Drug-related problems (DRP) are common in the elderly population, especially in people living with dementia (PwD). DRP are associated with adverse outcomes that could result in increased costs.

Objective: The objective of the study was to analyze the association between DRP and healthcare costs in PwD.

Serological interpretation--theoretical limits to information from blocking.

Contemporary immunogenetics uses a symbolism that tacitly assumes a one-to-one correspondence between genes, antigens, and antibody reagents that identify these. Thus a particular gene will be symbolized by an identifier, say X, and the reagent that supposedly uniquely identifies X is called anti-X. Ultimately, the precise relation between genes and antibody reagents will be determined by molecular techniques.

Symbolic reinterpretation of HLA gene products--impact on interpretation of HLA data at the molecular level.

In the HLA system genes are defined by antibody/antigen reactions and are denoted by single symbolic identifiers. This symbolization assumes a one-to-one correspondence between antibodies, antigens and genes. It is important, however, to label each reagent with symbols corresponding to all genes coding for antigens with which the reagent will react.